<DOC>
	<DOCNO>NCT01640340</DOCNO>
	<brief_summary>Palonosetron different ondansetron stay body longer may prevent nausea vomit long period time ondansetron . It standard practice use dexamethasone aprepitant either ondansetron palonosetron prevent nausea vomit cause highly emetogenic chemotherapy . Although combination commonly use , never compare . The purpose study record amount nausea vomiting , amount `` rescue '' medication use two different anti-emetic regimen</brief_summary>
	<brief_title>Ondansetron Versus Palonosetron Antiemetic Regimen Prior Highly Emetogenic Chemotherapy ( HEC )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The goal study evaluate overall complete response rate ( CR , emesis use rescue medication 0 120 hour chemotherapy ) two different antiemetic regimen ( palonosetron + aprepitant + dexamethasone ondansetron + aprepitant + dexamethasone ) patient undergo first cycle highly emetogenic chemotherapy ( HEC ) . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive palonosetron hydrochloride intravenously ( IV ) 30 minute prior chemotherapy day 1 , aprepitant orally ( PO ) 60 minute prior chemotherapy day 1-3 , dexamethasone PO 30 minute prior chemotherapy day 1-4 . ARM II : Patients receive ondansetron PO 30 minute prior chemotherapy day 1 aprepitant dexamethasone Arm I . After completion study treatment , patient follow 7 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Confirmed malignancy Chemotherapy naive treat low minimally emetogenic chemotherapy past ( defined National Comprehensive Cancer Network version [ v ] .2.201 Antiemetic Guidelines ) Scheduled receive first dose first cycle HEC Patients receive multiday chemotherapy , HEC portion must day 1 remain day chemotherapy must minimally emetogenic ( i.e . fluorouracil ) Performance status Eastern Cooperative Oncology Group ( ECOG ) grade 02 Able provide inform consent Able read write English someone translate record diary entry Able take oral medication Patients allow participate concurrent clinical trial , trial : Does mandate antiemetic regimen interferes study Allows antiemetic administration physician 's discretion Does prohibit patient participate study Patients must willing participate daily diary entry 5 day follow chemotherapy , agree 5 minute followup call day 2 3 day 5 , 6 7 Has stage IV ( metastatic ) disease Known hypersensitivity ondansetron , palonosetron , aprepitant , dexamethasone Have receive receive agent strong cytochrome P450 3A4 ( CYP450 3A4 ) inducer and/or inhibitor know cause clinically relevant drug interaction within one week prior study treatment continue day 5 ; vomit retch within 24 hour administration chemotherapy Grade 2 nausea great , accord Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v 4.0 ) within 24 hour administration chemotherapy Received antiemetic within 24 hour study drug administration , exclude use benzodiazepine Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5 time upper limit normal Total bilirubin &gt; 1.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>ondansetron</keyword>
	<keyword>palonosetron</keyword>
	<keyword>emetogenic chemotherapy</keyword>
	<keyword>HEC</keyword>
</DOC>